Premium
A PHASE I STUDY OF UTOMILUMAB (PF‐05082566), A 4‐1BB/CD137 AGONIST, IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH CD20 + NON‐HODGKIN'S LYMPHOMA
Author(s) -
Gopal A.,
Levy R.,
Houot R.,
Patel S.,
Hatake K.,
Popplewell L.,
Chen Y.,
Davis C.,
Huang B.,
Cesari R.,
Thall A.,
Woolfson A.,
Bartlett N.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_127
Subject(s) - medicine , lymphoma , rituximab , clinical endpoint , follicular lymphoma , pharmacodynamics , cd20 , mantle cell lymphoma , oncology , refractory (planetary science) , cd137 , pharmacokinetics , pharmacology , gastroenterology , clinical trial , immunotherapy , cancer , biology , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom